- Reference code :
- wf405
- Published date :
-
26 November 2001
- Expired date :
-
13 April 2029
AstraZeneca announced today that the U.S. Food and Drug Administration (FDA) granted six months’ market exclusivity for the ACE inhibitor ZESTRIL® (lisinopril) after the company complied with the FDA’s written request for information on the use of the medication in children.
The additional six months’ exclusivity extends AstraZeneca’s US market protection for currently marketed drug products containing lisinopril, which include ZESTRIL® and ZESTORETIC® (lisinopril and hydrochlorthiazide) Tablets, through June 29, 2002.
Further enquires to:
Media RelationsEmily Denney +44 (0)20 7304 5034 Steve Brown +44 (0)20 7304 5033 |
Investor RelationsJorgen Winroth +1 609 896 4148 Mina Blair-Robinson +44 (0)20 7304 5084 |
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 05:36 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
